The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Thymosin Alpha-1 exists at the intersection of two major immunological narratives: the discovery of the thymus as an essential immune organ, and the recognition that immune competence declines with age as the thymus involutes. Understanding both narratives is essential for understanding why Tα1 has attracted decades of clinical investigation.
The thymus is the primary organ of T-lymphocyte maturation. Bone marrow-derived T-cell precursors migrate to the thymus, where thymic epithelial cells provide the hormonal and cellular environment necessary for T-cell development — the process of antigen receptor rearrangement, positive selection (survival of T-cells that can recognize self-MHC), and negative selection (elimination of T-cells that recognize self antigens too strongly, preventing autoimmunity). The thymus is functionally critical in early childhood. It involutes progressively from puberty onward — shrinking in size, losing epithelial cell mass, and producing progressively fewer thymic hormones and fewer mature T-cells. By middle age, the thymus is largely replaced by fat. By old age, thymic output of naïve T-cells is dramatically reduced, contributing to the narrowing T-cell receptor repertoire and reduced immune adaptability that characterizes immune senescence.
In the 1960s and 1970s, researchers began identifying bioactive substances from thymic tissue that could promote T-cell development in thymectomized animals. Allan Goldstein at George Washington University (later University of Texas Medical Branch at Galveston) was a central figure in this work. Goldstein's laboratory isolated 'thymosin fraction 5' from calf thymus — a preparation containing multiple immunologically active peptides. From thymosin fraction 5, his team further purified and identified individual bioactive peptides including thymosin alpha-1, beta-thymosins, and other components. The landmark 1977 paper by Goldstein et al. in the Proceedings of the National Academy of Sciences established thymosin alpha-1 as a distinct 28-amino acid peptide with potent T-cell stimulating activity. The synthetic version was chemically identical to the natural human peptide.
The commercial development of Tα1 was pursued by Alpha-1 Biomedical (Goldstein's company) and later by SciClone Pharmaceuticals, which licensed and marketed the compound internationally as Zadaxin. SciClone built a substantial commercial franchise in Asia — particularly in China, where HBV infection is endemic and where the immune adjuvant approach to viral hepatitis had strong clinical support — as well as in Italy, where Tα1 received regulatory approval as an adjuvant for cancer immunotherapy. The compound was never taken through the full FDA New Drug Application process in the United States, leaving it in the off-label/compounding category for US users.
THE CENTRAL TENSION
Thymosin Alpha-1 is simultaneously the most clinically validated thymic peptide in history — approved in 37+ countries, 30+ RCTs, 11,000+ subjects, HBeAg seroconversion rate ratio 2.31 in HBV meta-analysis — and a compound whose most exciting recent indication (sepsis, specifically immune paralysis) was tested in the largest Phase 3 trial ever done for any thymic peptide (TESTS, n=1,106) and definitively failed to meet its primary endpoint. In the US it has navigated a complete regulatory round trip: Category 2 placement (2023), nomination withdrawal (2024), HHS announcement of Category 1 return (February 2026), PCAC formal review pending July 2026. In China it is used as adjuvant cancer therapy. In the US community it is used for immune optimization and longevity. The compound's cancer application presents the most nuanced safety picture: unlike most immune-stimulating compounds where cancer is a contraindication, Tα1's immune-calibrating mechanism means it may actually be beneficial as a cancer adjunct — but this requires specific clinical framing.
Thymosin Alpha-1 has had the most turbulent US regulatory history of any compound in this book. The 2023-2026 period includes a complete round trip: from widespread compounding, to FDA restriction, to nomination withdrawal, to pending re-authorization. Understanding this timeline is essential for any US-based practitioner or patient.
Before September 2023, Tα1 was a widely compounded peptide available from 503A pharmacies in the United States with a physician prescription. It occupied a well-established off-label niche: immune support in oncology patients, post-chemotherapy immune restoration, general immune optimization, and sometimes viral illness management. It was one of the more respected and evidence-backed compounds in functional/integrative medicine — backed by decades of international clinical trial data.
The FDA placed Tα1 (along with 18 other peptides) on Category 2 of the 503A Bulk Drug Substances interim list in September 2023. Category 2 compounds cannot be used in compounding preparations because they are under FDA review for safety concerns. The FDA's stated rationale for the broader Category 2 list included: insufficient published safety data for human clinical use; potential immunogenicity concerns; manufacturing and impurity concerns specific to peptide compounding. For Tα1, the immunogenicity concern was noted, despite the compound's extensive international clinical safety database. The practical consequence: compounding pharmacies immediately lost the ability to prepare Tα1 formulations; patients on Tα1 protocols lost access; physicians using Tα1 had to discontinue prescribing.
On September 20, 2024, the FDA announced that the nominations for five compounds — including Tα1 — had been withdrawn by their nominators. The withdrawal of nomination removed these compounds from Category 2 as of September 27, 2024. The FDA simultaneously referred these compounds to the Pharmacy Compounding Advisory Committee (PCAC) for formal review at upcoming October and December 2024 meetings, to determine whether they should be formally included in the 503A Bulks Regulation. The practical consequence of the nomination withdrawal: Tα1 was technically removed from Category 2, creating regulatory ambiguity — it was no longer explicitly restricted, but it had not received positive Category 1 status either.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on a widely distributed podcast interview that approximately 14 of the 19 originally restricted peptides would be returned to Category 1 status, including Tα1. This announcement preceded formal regulatory action but signaled the direction. On April 23, 2026, the formal removal of these peptides from Category 2 took effect. As of May 2026, Tα1 is no longer on Category 2 but has not yet received formal Category 1 listing.
The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24, 2026, to formally review Tα1 (and other peptides including CJC-1295, ipamorelin, AOD-9604, and Selank) for inclusion in the 503A Bulks Regulation — which would provide the formal Category 1 authorization for compounding. The July 2026 PCAC meeting is the next scheduled formal regulatory milestone for Tα1 in the United States. Practitioners and patients should monitor PCAC outcomes before making definitive prescribing or access decisions based on anticipated Category 1 status.
Date
Event
Practical Impact
Pre-Sept 2023
Category 1 — freely compoundable with physician prescription
Widely available from 503A pharmacies
Sept 2023
Category 2 placement by FDA — compounding restricted
Compounding pharmacies stop producing; patient access disrupted
Sept 27, 2024
Nomination withdrawn; removed from Category 2; referred to PCAC
Regulatory ambiguity; technically not restricted, not yet authorized
Feb 27, 2026
HHS Kennedy announcement: ~14 peptides returning to Category 1 including Tα1
Political signal; formal action pending
April 23, 2026
Formal removal from Category 2 takes effect
No longer restricted; still awaiting formal Category 1 confirmation
July 23-24, 2026
PCAC review scheduled for Tα1 and related peptides
Formal Category 1 status expected if PCAC supports it
Thymosin Alpha-1: 28 amino acids, N-terminally acetylated at serine (Ac-Ser). Full sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Highly acidic — loaded with aspartate (D) and glutamate (E) residues producing a net negative charge at physiological pH. MW 3,108.43 Da. CAS 62304-98-7. Derived from prothymosin alpha, a 109-amino acid nuclear protein produced by thymic epithelial cells, which is proteolytically processed to release the active N-terminal Tα1 fragment. Thymalfasin is the INN (international nonproprietary name) for the synthetic form, which is chemically identical to the endogenous human peptide — an important distinction from many peptides in this book that are modified analogs.
The primary mechanism through which Tα1 activates innate immunity: Toll-like receptor (TLR) engagement on dendritic cells and macrophages. TLRs are pattern recognition receptors that detect pathogen-associated molecular patterns (PAMPs) and initiate innate immune responses. Tα1 engages multiple TLRs simultaneously, acting as an endogenous danger signal: TLR2 on myeloid dendritic cells — activates NF-κB → pro-inflammatory cytokines (IL-12, TNF-α, IL-6); promotes DC maturation and upregulation of antigen-presentation molecules (MHC-II, CD80, CD86). TLR9 on plasmacytoid dendritic cells (pDCs) — activates IRF3/IRF7 → type I interferon production (IFN-α, IFN-β); type I interferons are central to antiviral immunity and are one of the primary mechanisms by which Tα1 augments clearance of viral pathogens. This TLR2/TLR9 dual engagement on different dendritic cell subsets explains Tα1's ability to coordinate both myeloid (conventional DC) and lymphoid (pDC) branches of innate immunity simultaneously.
Through TLR activation and downstream cytokine production, mature dendritic cells present antigen more effectively to naïve T-cells and polarize the adaptive immune response: Th1 polarization — IL-12 from mature myeloid DCs drives CD4+ T helper cells toward Th1 phenotype; Th1 cytokines (IFN-γ, IL-2) are the primary drivers of intracellular pathogen clearance and antitumor cytotoxic immunity. CD8+ cytotoxic T-cell activation — mature DCs cross-present antigens to naïve CD8+ T-cells, generating cytotoxic effector cells capable of killing virus-infected cells and tumor cells. NK cell activation — Tα1 directly stimulates natural killer cell cytotoxic activity against virus-infected and tumor cells; NK cells are a first-line innate defense that can kill targets without MHC restriction. This activation pattern — Th1 polarization, CTL generation, NK enhancement — constitutes the core antiviral and antitumor immune profile that explains Tα1's clinical applications in HBV, HCV, and cancer.
THE IDO MECHANISM — WHY THYMOSIN ALPHA-1 IS AN IMMUNOMODULATOR, NOT A SIMPLE IMMUNOSTIMULANT
The most important mechanistic insight in the modern Tα1 literature comes from Romani et al. (2006, Blood): Tα1 activates dendritic cell tryptophan catabolism through upregulation of IDO (indoleamine 2,3-dioxygenase), the enzyme that metabolizes tryptophan into kynurenine pathway metabolites. IDO activation in DCs is a tolerogenic signal: kynurenines suppress T-cell proliferation; IDO-expressing DCs generate regulatory T-cells (Tregs) rather than effector T-cells. This means Tα1 simultaneously: (1) activates TLR2/TLR9 → DC maturation → Th1/CTL/NK immune activation (pro-immune); AND (2) activates IDO → kynurenine pathway → Treg generation → immune tolerance calibration (tolerogenic). The net result is bidirectional immune calibration — Tα1 can enhance responses to infection and tumors while preventing the excessive inflammatory signaling that causes immune-mediated tissue damage. This is the mechanistic basis for calling Tα1 an immunomodulator rather than an immunostimulant. A pure immunostimulant would worsen autoimmune disease; an immunomodulator with this bidirectional profile has the potential to be beneficial even in contexts of immune dysregulation.
In aged or immunocompromised individuals, the thymus has involuted and produces fewer naïve T-cells and thymic hormones. Tα1 partially compensates for this reduced endogenous production: it promotes differentiation of thymocytes into functional mature T-cells; upregulates CD3, CD4, CD8 expression on T-cell surfaces; enhances T-cell receptor diversity; and restores T-cell responsiveness to mitogens and antigens. This mechanism is the conceptual basis for Tα1's use in immune senescence contexts — aging, post-chemotherapy immune suppression, HIV-related immune deficiency — where the compound substitutes for the declining endogenous thymic signal.
Thymosin Alpha-1 is an endogenous peptide produced by thymic epithelial cells throughout life, but its production is tightly linked to thymic mass and activity. The thymus undergoes progressive involution beginning at puberty: thymic mass peaks in childhood (approximately 30-40 grams), begins declining at puberty under sex hormone influence, and continues involuting through adulthood. By age 40-50, thymic parenchyma (functional tissue) is largely replaced by fat — the 'thymic graveyard.' By age 70+, functional thymic tissue may be reduced to less than 10-15% of peak mass. The consequences for endogenous Tα1 production: serum Tα1 levels have been documented to decline approximately 40-60% from young adult levels in older adults. This age-associated decline parallels the well-documented narrowing of the T-cell receptor repertoire (reduced TCR diversity), decreased naïve T-cell output from the thymus, impaired response to novel antigens, and reduced vaccine efficacy that characterize immune senescence. The restoration framework: administering exogenous Tα1 to aging adults aims to substitute for the declining endogenous thymic signal, potentially maintaining immune competence beyond what the involuted thymus can sustain naturally. This is pharmacologically analogous to hormone replacement in other systems — GH restoration in somatopause, testosterone replacement in andropause. Whether the analogy holds clinically — whether restoring serum Tα1 produces the same immune function restoration as maintaining endogenous production — has not been demonstrated in prospective controlled trials in healthy aging humans.
Thymosin Alpha-1 has one of the largest controlled trial databases of any peptide compound covered in this book — considerably more rigorous clinical evidence than almost any peptide used in community/longevity contexts. The evidence is condition-specific, concentrated primarily in viral hepatitis, and meaningfully complicated by the recent TESTS sepsis trial.
Chronic hepatitis B (CHB) represents the most extensive and high-quality evidence base for any thymic peptide in clinical history. The key evidence: (1) Chien et al. (1998, Hepatology): landmark RCT of Tα1 + interferon-alpha vs IFN-alpha alone vs placebo in HBeAg-positive CHB. Tα1 + IFN combination achieved 50% sustained virological response at 18 months; IFN alone achieved 25%; placebo 13%. The combination was better tolerated than high-dose IFN monotherapy, with fewer flu-like symptoms and less myelosuppression. (2) Pooled analysis of 5 RCTs (n=425, Camerini/Garaci data): HBeAg seroconversion rate ratio of 2.31 (95% CI 1.52-3.51, p<0.001) for Tα1 vs control. HBeAg seroconversion is a clinically meaningful endpoint — it indicates immune-mediated control of HBV replication. (3) Meta-analysis of 8 RCTs (n=898, You et al., 2006, Journal of Viral Hepatitis): Tα1 monotherapy achieved sustained virological response in approximately 36% vs 19% for untreated controls; odds ratio 2.67 (95% CI 1.76-4.05). (4) Combination with nucleos(t)ide analogs: 2019 meta-analysis of 14 RCTs evaluating Tα1 + entecavir vs entecavir alone showed enhanced HBeAg seroconversion and HBsAg clearance. (5) Zhang et al. (2009, Virology Journal) meta-analysis of lamivudine + Tα1: superior to lamivudine alone — HBeAg seroconversion 45.1% vs 15.2% (p<0.00001). This is the strongest controlled evidence base for Tα1 across all indications.
The mechanistic reason HBV is the ideal Tα1 indication: chronic hepatitis B is an immunological failure disease. HBV is not directly cytotoxic to hepatocytes — liver damage in HBV is caused by the immune response to infected cells, and the failure to clear HBV infection results from an inadequate, exhausted T-cell response to HBV antigens. In chronic HBV, HBV-specific CD4+ and CD8+ T-cells are functionally exhausted — they express inhibitory markers (PD-1, TIM-3, LAG-3) and fail to produce the IFN-γ and cytotoxic activity needed to clear infected cells. Tα1 restores this dysfunctional T-cell response by activating DC maturation (the upstream antigen-presenting cells that re-prime T-cells), shifting toward Th1 cytokine production, and enhancing NK cell cytotoxicity. The IDO-mediated Treg calibration prevents excessive immune-mediated liver damage during viral clearance. This mechanistic fit between Tα1's pharmacology and HBV pathophysiology explains why HBV is where the compound shows its most impressive clinical results.
The HCV evidence for Tα1 is positive in direction but less robust than HBV. Multiple RCTs evaluated Tα1 as an adjunct to interferon-based regimens (the standard pre-DAA era treatment). Meta-analyses showed enhanced sustained virological response rates with Tα1 + IFN combination vs IFN alone. The relevance of this evidence has substantially declined since the development of direct-acting antivirals (DAAs) — sofosbuvir, ledipasvir, and related compounds — which achieve >95% SVR in HCV with oral administration. Tα1 as an HCV adjunct is largely superseded in populations with DAA access. Grade B — adequate RCT evidence in a now partially obsolete indication.
THE TESTS TRIAL — THE MOST IMPORTANT RECENT DEVELOPMENT IN THYMOSIN ALPHA-1 RESEARCH
The clinical trajectory of Tα1 in sepsis represents one of the most instructive examples of how Phase 2 signals can fail to replicate at Phase 3 scale. ETASS Trial (Wu et al., 2013, Critical Care Medicine): n=361 severe sepsis patients in China; randomized, placebo-controlled; Tα1 1.6 mg SubQ twice daily for 5 days. Result: 28-day mortality 26.0% (Tα1) vs 35.0% (standard care), RR 0.74 (95% CI 0.54-1.02, p=0.049 by log-rank). A positive signal at marginal statistical significance; mechanistically coherent (sepsis often involves immune paralysis where Tα1's immune restoration could help). Clinical enthusiasm followed — widespread use in Chinese ICUs. TESTS Trial (Wu et al., 2025, BMJ, n=1,106): the definitive multicenter, double-blind, randomized, placebo-controlled Phase 3 trial. 22 centers. Enrolled 1,106 sepsis patients. Primary endpoint: 28-day all-cause mortality. Result: 23.4% (Tα1) vs 24.1% (placebo), HR 0.99 (95% CI 0.82-1.19, p=0.93). Definitively negative. The sepsis indication for unselected sepsis patients cannot be supported by Phase 3 evidence as of 2025. A 2025 Frontiers in Cellular and Infection Microbiology systematic review and meta-analysis of all sepsis RCTs suggested possible benefit in immunosuppressed subgroups — but this requires confirmation in subgroup-specific trials before it can guide practice.
Multiple Chinese RCTs evaluated Tα1 in severe COVID-19 during 2020-2021. Liu et al. (2020, Science Immunology): Tα1 significantly reduced mortality in severe COVID-19 patients (16.4% vs 28.0% in controls); mechanistically, Tα1 restored lymphocyte counts and reversed T-cell exhaustion markers (PD-1, Tim-3 expression on CD4+ and CD8+ T-cells) that were associated with COVID-19 severity. Several additional Chinese RCTs showed similar benefit on immune markers. The evidence is Grade B — multiple positive trials in a specific population (severe COVID-19 with lymphopenia), consistent with Tα1's known mechanism (reversing immune exhaustion and restoring T-cell function). Limitations: most trials were conducted in single Chinese centers during the pandemic with varying methodological rigor.
Tα1 is approved in Italy specifically as an immunological adjuvant for melanoma. The mechanism: Tα1 primes dendritic cells and T-cells toward antitumor activity, potentially enhancing the efficacy of chemotherapy or checkpoint inhibitor therapy. The IDO-Treg pathway provides immune tolerance calibration that may prevent immune-mediated toxicity from combination immunotherapy. Chinese clinical experience includes substantial Phase 3 data for hepatocellular carcinoma (HCC) where Tα1 + chemotherapy is studied as a standard combination. The 'prime and boost' strategy — Tα1 (prime dendritic cells and T-cells) followed by checkpoint inhibitor (boost by removing PD-1/PD-L1 brakes) — is being evaluated in ongoing trials in HCC, NSCLC, and gastric cancer. The cancer application is the most important exception to the conventional 'immune activation as contraindication in cancer' framing: Tα1's bidirectional immunomodulatory profile may make it specifically beneficial as a cancer adjunct, not contraindicated.
Indication
Grade
Key Evidence
Current Status
Chronic Hepatitis B
A
Pooled 5 RCTs (n=425): HBeAg seroconversion RR 2.31; meta-analysis 8 RCTs (n=898): OR 2.67; Chien 1998: 50% vs 25% sustained response with IFN combination
Standard of care in China; approved Zadaxin indication
Chronic Hepatitis C
B
Multiple RCTs positive; combination with IFN superior to IFN alone
Largely superseded by DAAs (sofosbuvir, etc.) in populations with access
Sepsis (general)
D — NEGATIVE Phase 3
ETASS 2013 positive (n=361); TESTS 2025 NEGATIVE (n=1,106, BMJ)
Primary endpoint not met; unestablished for unselected sepsis
Sepsis (immunosuppressed subgroup)
C
TESTS subgroup analysis; 2025 meta-analysis signal
Hypothesis-generating only; requires specific subgroup trial
COVID-19 severe (lymphopenic)
B
Liu 2020 Science Immunology; multiple Chinese RCTs; mortality reduction + T-cell restoration
Consistent signal; pandemic-context evidence; not replicated post-pandemic
Cancer adjunct (melanoma)
B
Approved in Italy; Phase 3 data from China in HCC; checkpoint inhibitor synergy emerging
Active clinical development; IDO tolerance mechanism supports rationale
General immune optimization (healthy adults)
E
No controlled evidence; community use based on mechanism extrapolation
Off-label; Grade E
Autoimmune conditions
D — Theoretical caution
No controlled evidence; bidirectional IDO mechanism provides some rationale but risk of activation cannot be excluded
Not studied; use with physician oversight only
The standard framing for most immune-activating compounds is a simple contraindication in autoimmune disease: if the immune system is already attacking self-tissue, stimulating it further makes things worse. Thymosin Alpha-1's IDO-Treg mechanism makes this framing more nuanced — but not eliminated.
The theoretical case that Tα1 might be used cautiously in some autoimmune contexts rests on the IDO mechanism: Tα1 activates IDO in dendritic cells, generating kynurenines and Tregs that suppress excessive immune activation. If the autoimmune pathology involves insufficient Treg-mediated tolerance (a proposed mechanism in several autoimmune conditions including IBD, multiple sclerosis, and rheumatoid arthritis), then Tα1's Treg-promoting activity might theoretically recalibrate toward tolerance rather than amplify the attack. The Romani 2006 Blood paper specifically discusses Tα1's potential to 'establish a regulatory environment for balance of inflammation and tolerance.'
The practical reality: no controlled trial has evaluated Tα1 in autoimmune conditions. The IDO-Treg mechanism is real, but whether it dominates over the Th1-activating and NK-activating effects in any given autoimmune condition is not established. The risk of worsening autoimmune disease through Th1 activation cannot be excluded based on existing evidence. The only evidence-based position: Tα1 is not established as safe or effective in autoimmune disease; physician supervision and case-by-case assessment are required for any autoimmune patient considering Tα1.
The parallel question for patients already on immunosuppressive medications: Tα1's immune-activating effects could theoretically counteract immunosuppressive therapies (corticosteroids, methotrexate, biologics). Conversely, the IDO-Treg pathway might complement certain immunomodulatory approaches. This interaction profile has not been formally studied. Any patient on immunosuppressive therapy for autoimmune disease should have this discussion explicitly with their rheumatologist or immunologist before initiating Tα1.
AUTOIMMUNE CONDITIONS — NUANCED CAUTION, NOT BLANKET CONTRAINDICATION
Tα1 is NOT subject to the same absolute cancer/tumor-growth contraindication that applies to IGF-1-based compounds or growth factors. The cancer concern for Tα1 is different: the question is whether immune activation might interfere with cancer treatment or worsen paraneoplastic immunological complications. For autoimmune disease: the IDO mechanism provides a theoretically plausible path to benefit; the Th1-activating mechanism creates a theoretical path to harm; no controlled evidence resolves this tension in specific autoimmune conditions. Physician consultation required. Active, severe autoimmune flare: avoid. Stable autoimmune disease: discuss with rheumatologist. Cancer adjunct: different from contraindication — see Section 3.5.
Tα1's safety profile is among the most extensively characterized of any thymic peptide in clinical medicine — the international Zadaxin clinical program has generated safety data across 30+ RCTs and 11,000+ subjects. Key findings: No serious drug-related adverse events attributable to Tα1 were reported in the ETASS sepsis trial (n=361) or the TESTS sepsis trial (n=1,106). No dose-limiting toxicity observed at clinical doses. No organ toxicity — hepatic, renal, or cardiac adverse effects not documented. No HPTA suppression — Tα1 does not affect the hypothalamic-pituitary axis. No addiction or dependence liability. No withdrawal syndrome. The most commonly reported side effects across clinical trials: mild transient injection site reactions (redness, swelling at SubQ injection site — typical for protein injections); mild fever or flu-like symptoms (occasional; consistent with immune activation in specific contexts); mild gastrointestinal complaints (rare). Overall safety assessment: favorably tolerated across a very large controlled trial database.
Unlike growth factor compounds (IGF-LR3, tesamorelin) where active malignancy is a contraindication based on tumor-promoting mechanisms, Tα1's relationship with cancer is fundamentally different. Tα1 is used as a cancer adjunct — to enhance immune-mediated antitumor activity — in several approved and investigational contexts. The Italian approval covers melanoma; the Chinese clinical experience includes HCC. The IDO-mediated tolerance calibration provides a rational mechanism for combining Tα1 with chemotherapy or checkpoint inhibitors without excessive immune toxicity. The appropriate framing: Tα1 in active malignancy should be discussed with the treating oncologist — not reflexively avoided. In some oncological contexts, it may be specifically indicated; in others, the interaction with cancer treatment regimens requires evaluation.
Standard Zadaxin clinical dosing: 1.6 mg SubQ injection. Frequency varies by indication: Chronic hepatitis B: 1.6 mg SubQ twice weekly for 6 months (sometimes 12 months in combination protocols). Hepatitis C (historical): 1.6 mg SubQ twice weekly. Sepsis (ETASS/TESTS protocol): 1.6 mg SubQ twice daily for 5 days. Cancer adjunct (variable): 1.6 mg SubQ 2-3x weekly during chemotherapy or immunotherapy cycles. Community immune optimization protocols: 1.6 mg SubQ 1-3x weekly; duration variable (3 months, 6 months, or continuous with monitoring). The 1.6 mg dose is the pharmacologically established reference dose from the clinical trial database. There is no controlled evidence for dose escalation beyond 1.6 mg in clinical contexts.
Tα1 is supplied as lyophilized powder, typically in 1.6 mg vials. Reconstitution: typically with bacteriostatic water or sterile water for injection. SubQ injection is the standard route; IM is not typically used. The peptide is stable after reconstitution at 2-8°C for a limited period (days to weeks depending on formulation). Unlike GHRH analogs that require acetic acid pH for stability, Tα1 is more stable at physiological pH — bacteriostatic water reconstitution is appropriate. Storage of lyophilized powder: 2-8°C or room temperature depending on manufacturer specifications; protect from light.
The most important C3 confusion in the thymosin family: Tα1 and Tβ4 (thymosin beta-4, marketed in research as TB-500) share the 'thymosin' name but have essentially no mechanistic overlap. Tα1: 28 amino acid immune modulator; TLR activation; DC maturation; T-cell polarization; NK activation; IDO tolerance calibration. Clinically validated for hepatitis B, cancer adjunct, sepsis. Acts on the immune system. Tβ4: 43 amino acid tissue repair peptide; primary mechanism is G-actin sequestration and actin polymerization regulation; cardiac protection; wound healing; anti-inflammatory; angiogenic. Acts on tissue repair and regeneration. They are produced by different cell types, act through completely different receptors and pathways, and are used for completely different indications. The only similarity: both are endogenous thymic peptides with 'thymosin' in their names. Using either compound based on data from the other is a category error.
Zadaxin approval in 37+ countries, including by Chinese NMPA and Italian AIFA, does not constitute FDA approval in the United States. These are separate regulatory bodies with separate processes. FDA approval requires filing an IND, conducting US-regulated Phase 1, 2, and 3 trials, and submitting an NDA or BLA to the FDA. Tα1 has not completed this process in the United States. The international approval is pharmacologically meaningful — it establishes a robust safety database and validates the clinical rationale — but it does not change the US regulatory status, which is off-label/compounding.
TESTS (2025) showed that Tα1 does not reduce 28-day mortality in unselected sepsis patients in a definitive Phase 3 trial. This does not mean Tα1 is ineffective for other indications. The hepatitis B evidence (Grade A) was not tested in TESTS. The cancer adjunct evidence was not tested in TESTS. The COVID-19 evidence was not tested in TESTS. TESTS addressed one specific indication — unselected sepsis — and found the primary endpoint negative. The correct inference: sepsis (general, unselected) is no longer a supportable indication for Tα1. The broader Tα1 evidence base for viral hepatitis and cancer adjunct use is not undermined by the TESTS result.
The favorable safety profile documented in 30+ RCTs across 11,000+ subjects means Tα1 has a well-characterized, manageable safety database with no documented dose-limiting toxicity. It does not mean the compound is physiologically inert. Immune activation effects — particularly in the context of autoimmune disease, organ transplantation, or active immunotherapy regimens — require careful clinical evaluation. The favorable safety profile supports use in appropriate clinical contexts with appropriate oversight; it does not support the inference that the compound can be used without assessment in any patient.
The community use of Tα1 for 'immune support,' 'immune optimization,' or 'longevity immune maintenance' in otherwise healthy adults is Grade E evidence — community consensus without controlled trials in this population. The mechanistic rationale is coherent: declining thymic function and reduced endogenous Tα1 with aging create a biological opportunity for restoration. The clinical evidence from viral hepatitis and sepsis contexts confirms the compound's immunological activity in contexts of immune insufficiency. Whether this translates to meaningful benefit in immunologically normal aging adults has not been studied. The favorable safety profile makes a trial reasonable; outcome claims in this population should be framed as unestablished.
Physician-supervised clinical contexts where Tα1 has the strongest evidence basis: HBV carriers or active CHB patients not achieving optimal response on standard nucleos(t)ide therapy — Tα1 as an add-on to entecavir or tenofovir based on multiple positive RCTs and meta-analyses. Cancer patients undergoing chemotherapy or immunotherapy — particularly where immune suppression from chemotherapy is clinically significant; Tα1 as adjuvant immune support based on Chinese and Italian clinical data. Post-chemotherapy immune restoration — where T-cell counts and immune function are depressed following cytotoxic therapy. Post-COVID immune dysregulation with persistent lymphopenia — based on Liu 2020 and related RCT data showing Tα1 restores lymphocyte counts and reverses T-cell exhaustion.
For otherwise healthy adults using Tα1 for general immune optimization or longevity support, the most common community protocols: 1.6 mg SubQ 2-3x weekly for 4-12 weeks (a defined course); or 1.6 mg SubQ weekly as maintenance. Some practitioners use 0.8 mg doses (half of the clinical reference dose) for immune maintenance in healthy adults, reasoning that the endogenous replacement dose may be lower than the therapeutic dose used for specific pathologies. Neither protocol has been evaluated in controlled trials in healthy adults. The favorable safety profile from the clinical database supports reasonable risk tolerability; outcome claims in this population remain unestablished.
In the longevity medicine framework, Tα1's appeal is the immune senescence hypothesis: as the thymus involutes and endogenous Tα1 production declines, naïve T-cell output and immune adaptability diminish. Supplementing Tα1 potentially maintains thymic output and immune responsiveness into aging. This is pharmacologically coherent; it is not evidence-based in healthy aging populations. The typical longevity clinic protocol: Tα1 1.6 mg SubQ twice weekly for 6-12 weeks per year, sometimes in combination with peptide immune-support stacks (BPC-157 for GI integrity, GHK-Cu for anti-inflammatory support, thymalin equivalents). No controlled evidence validates any specific combination or duration for the longevity use case.
One application where Tα1 has been studied in non-diseased populations is as an influenza vaccine adjuvant in elderly subjects. Multiple studies (including Panatto et al. and related Italian research) have evaluated Tα1 administered alongside influenza vaccination in older adults with age-related immune senescence. Findings: Tα1 co-administration improved serological response to influenza vaccination in elderly subjects, producing higher antibody titers and better seroprotection rates compared to vaccination alone. This is the closest available controlled evidence to a 'healthy aging immune optimization' application — though it is vaccine-adjuvant specific, not general immune optimization. Grade B — consistent direction, multiple studies, specific application (vaccination adjuvant). This data point is pharmacologically meaningful: it demonstrates that Tα1 can enhance functional immune responses in aging adults in a measurable, endpoint-defined way. Whether this translates to benefit outside of vaccination contexts requires extrapolation.
In community use, Tα1 is frequently combined with other immune-modulating or tissue-repair peptides. The most common community stacking patterns: Tα1 + BPC-157: BPC-157's GI and systemic repair effects complement Tα1's immune restoration; no known pharmacological interaction; combined use is mechanistically rational if different goals are being addressed. Tα1 + peptide thymulin or thymic peptide preparations: some practitioners combine multiple thymic peptides for 'comprehensive thymic support' — the additive vs redundant effects of multiple thymic peptides have not been studied. Tα1 + LDN (low dose naltrexone): both are immunomodulatory; LDN through TLR4/microglial modulation; Tα1 through TLR2/TLR9/DC maturation. Mechanistically complementary; no interaction data. Tα1 + GHK-Cu: GHK-Cu is anti-inflammatory; Tα1 is immune-activating; the combination may provide balanced immune support without amplifying inflammatory pathways. No formal evidence for any combination; stacking decisions should be made with physician oversight.
A 2025 Expert Consensus on Clinical Application of Thymosin Alpha-1, published by the National Clinical Research Center for Infectious Diseases (China) and collaborating institutions, assessed the quality of evidence across Tα1's major indications and provided graded recommendations. The consensus affirmed Grade A recommendations for HBV combination therapy; acknowledged the negative TESTS sepsis trial while noting possible subgroup benefit; and identified COVID-19, cancer adjunct, and general immune deficiency as areas warranting further investigation. This expert consensus represents the most current authoritative summary of clinical Tα1 guidance from the research community that has generated the most evidence for the compound.
Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. (1977). Purification and biological activity of thymosin, a hormone of the thymus gland. Proceedings of the National Academy of Sciences USA. 69(7):1800-1803. [Original isolation and characterization of thymosin fraction 5; foundational paper establishing thymic peptides as immunologically active.]
Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E. (2006). Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 108(7):2265-2274. PMID 16804115. [The IDO/kynurenine/Treg mechanism paper; establishes Tα1 as immunomodulator vs immunostimulant; foundational mechanistic work.]
Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. (1998). Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 27(5):1383-1387. [Landmark RCT; Tα1 + IFN-alpha: 50% sustained response vs 25% IFN alone vs 13% placebo; combination benefit and tolerability advantage established.]
Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. (2009). Lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B: a meta-analysis of 8 trials (n=583). Journal of Virology. PMC2693103. [HBeAg seroconversion 45.1% vs 15.2% (p<0.00001); combination superiority.]
Wu J, Zhou L, Liu J, Ma G, Ren J, He Z, Tian Y, Zhou X, Dong H, Wang H, Wang M, Wei S, Zhang X, Cheng B, Xu J, Xia J, Ma X. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized trial. Critical Care Medicine. [n=361; 28-day mortality 26.0% vs 35.0%, p=0.049. The positive Phase 2 signal.]
Wu J et al. (2025). The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 388:e080561. PMC11780596. [n=1,106; 28-day mortality 23.4% vs 24.1%, HR 0.99, p=0.93. NEGATIVE. The definitive Phase 3 result.]
Liu Y et al. (2020). Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells. Clinical Infectious Diseases. [Key COVID-19 mortality reduction RCT; lymphocyte restoration; T-cell exhaustion reversal mechanism documented.]
FDA notice September 20, 2024: removal of Tα1, AOD-9604, CJC-1295, ipamorelin, and Selank from Category 2 following withdrawal of nominations; referral to PCAC for 503A Bulks Regulation review. Federal Register. [The formal Category 2 withdrawal; PCAC process initiation.]
Thymosin Alpha-1 is genuinely one of the most clinically evidenced thymic peptides in existence — and the TESTS 2025 trial result requires an honest update to the sepsis narrative that much of the community has not yet processed.
The central tension resolved: Tα1 has earned its Grade A status in HBV — the meta-analyses are rigorous, the seroconversion rate ratio of 2.31 is clinically significant, and the compound is standard of care in markets where HBV management is most important. The cancer adjunct application is pharmacologically coherent, clinically supported in specific approved markets, and growing as checkpoint inhibitor combination approaches develop. These are real, evidence-based applications. The sepsis story requires an honest update: TESTS (n=1,106, BMJ 2025) was definitively negative. The ETASS positive signal did not replicate at Phase 3 scale in unselected sepsis. Any clinical or community discussion of Tα1 for sepsis should acknowledge this. The community immune optimization use is Grade E — mechanistically coherent, safety-supported, evidence-absent for the healthy aging population that forms most of the community user base in the United States.
— End of Thymosin Alpha-1 —
THE PEPTIDE BIBLE | Thymosin Alpha-1 | For Research & Educational Purposes Only
Thymosin Alpha-1 (Tα1 / Thymalfasin / Zadaxin): 28-amino acid endogenous thymic peptide. N-terminally acetylated. Sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. MW 3,108.43 Da. Isolated by Goldstein et al. 1977 from calf thymus. Endogenous Tα1 produced by thymic epithelial cells from prothymosin alpha precursor; declines 40-60% with thymic involution and aging. Synthetic form: thymalfasin = Zadaxin (SciClone). MECHANISM: (1) TLR2/TLR9 agonism on myeloid and plasmacytoid DCs → NF-κB/IRF3/IRF7 → DC maturation, IL-12, IFN-α/β, Th1 polarization, NK activation; (2) IDO activation in DCs → tryptophan → kynurenines → Treg generation → immune tolerance calibration (Romani 2006, Blood). Bidirectional immunomodulator — enhances protective immunity + calibrates tolerance. NOT a simple immunostimulant. REGULATORY: Zadaxin approved 37+ countries (China, Italy, SE Asia, LatAm) for HBV, HCV, cancer adjunct. NOT FDA-approved US. US TIMELINE: Category 2 (Sept 2023) → nomination withdrawn, removed from Category 2 (Sept 27, 2024) → HHS announcement returning to Category 1 (Feb 27, 2026) → formal Category 2 removal (April 23, 2026) → PCAC review pending July 23-24, 2026. EVIDENCE — HBV (Grade A): meta-analysis 5 RCTs (n=425): HBeAg seroconversion RR 2.31 (CI 1.52-3.51); meta-analysis 8 RCTs (n=898): sustained response OR 2.67; Chien 1998: 50% vs 25% with IFN combination; lamivudine + Tα1: 45.1% vs 15.2% seroconversion (p<0.00001). HCV (Grade B): combination with IFN superior; largely superseded by DAAs. SEPSIS: ETASS 2013 (n=361) positive (26% vs 35% mortality, p=0.049); TESTS 2025 (n=1,106, BMJ) NEGATIVE — HR 0.99, p=0.93; primary endpoint not met; unselected sepsis no longer a supported indication. COVID-19 (Grade B): Liu 2020 Science Immunology — mortality reduction; lymphocyte restoration; T-cell exhaustion reversal. Cancer adjunct (Grade B): Italy melanoma approval; Chinese HCC Phase 3 data; IDO mechanism supports checkpoint inhibitor synergy. AUTOIMMUNE: not contraindicated in the growth-factor sense; bidirectional mechanism creates nuance; no controlled trial; physician consultation required. CANCER: NOT a standard active malignancy contraindication — used as cancer adjunct in established markets; discuss with oncologist. DOSING: 1.6 mg SubQ (twice weekly to twice daily depending on indication). SAFETY: exceptional across 30+ RCTs, 11,000+ subjects; no dose-limiting toxicity; mild injection site reactions; no HPTA effect; no dependence. Tα1 vs Tβ4 (TB-500): completely different — name only commonality. WADA: not prohibited.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.